Related Experiment Video
Updated: Mar 10, 2026

A Luciferase-fluorescent Reporter Influenza Virus for Live Imaging and Quantification of Viral Infection
Published on: August 14, 2019
The "Fluad Case" in Italy: Could it have been dealt differently?
Miriam Levi1, Ersilia Sinisgalli1, Chiara Lorini1
1a Department of Health Sciences , University of Florence , Florence , Italy.
Abstract:
During the influenza vaccination campaign 2014-2015, the reporting of 3 deaths within 48 hours of vaccination with Fluad brought the Italian Medicines Agency (AIFA) to pronounce the withdrawal of 2 batches of vaccine, based on the precautionary principle. Investigations by the Italian National Institute of Health, and by the Pharmacovigilance Risk Assessment Committee (PRAC), the committee at the European Medicines Agency (EMA) responsible for monitoring and assessing the safety profiles of human drugs, concluded that there was a lack of causality between the reported deaths and the vaccines administered. However, the media impact of the decision taken by AIFA, resulted in a lower influenza vaccination coverage compared with the previous years. The aim of our study was to identify possible critical points that may have led to a non-perfect management of the event. A review of the regulatory framework in place was performed, with a particular focus on the Guidelines on Good Pharmacovigilance Practices developed by the EMA to facilitate the signal management process. The management of reports involves the following steps: signal detection, its validation and confirmation, analysis and prioritization, assessment, recommendations for action and the exchange of information. In our opinion, both the signal detection phase and the phase of validation have been critical: the withdrawal of vaccine batches is possible even in case of a single suspected serious adverse reaction. However, aspects such as the biological plausibility, the presence of potential alternative causes and previous awareness should also be considered. Furthermore, the number of reported deaths was consistent with the expected background mortality rate in the vaccinated cohort. The disproportionate media coverage given to the AIFA decision resulted in a reduced vaccine confidence in the general population and in a decreased immunization coverage. Improving the communication on vaccine safety issues is crucial at this stage to restore a climate of trust in this powerful tool for primary prevention.
Insights
Following three deaths after Fluad vaccination, regulatory action led to lower vaccine confidence. Investigations found no causal link, highlighting communication gaps in vaccine safety management.
Area of Science:
- Pharmacovigilance and Vaccine Safety
- Regulatory Science
- Public Health Communication
Background:
- The 2014-2015 influenza vaccination campaign saw reported deaths post-Fluad vaccination, prompting batch withdrawal by the Italian Medicines Agency (AIFA).
- Subsequent investigations by the Italian National Institute of Health and the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) found no causal link between the deaths and the vaccine.
Purpose of the Study:
- To identify critical points in the management of vaccine safety events.
- To analyze the regulatory framework and pharmacovigilance guidelines for signal management.
- To understand the impact of media coverage on vaccine confidence and coverage.
Main Methods:
- Review of the regulatory framework, focusing on EMA's Guidelines on Good Pharmacovigilance Practices.
- Analysis of the signal management process, including detection, validation, assessment, and information exchange.
- Evaluation of the media's role in public perception and vaccine uptake.
Main Results:
- Signal detection and validation phases were identified as critical, with potential for improvement in considering factors like biological plausibility and background mortality.
- The number of reported deaths was consistent with the expected background mortality rate.
- Disproportionate media coverage of AIFA's decision negatively impacted vaccine confidence and coverage.
Conclusions:
- Improved communication strategies are essential to address vaccine safety concerns and restore public trust.
- A balanced approach to pharmacovigilance signal management, considering multiple factors, is crucial.
- Effective communication can mitigate the negative impact of adverse event reporting on public health initiatives like vaccination programs.
More Related Videos
11:14Ex Vivo Infection of Human Lymphoid Tissue and Female Genital Mucosa with Human Immunodeficiency Virus 1 and Histoculture
Published on: October 12, 2018
09:03Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Published on: June 19, 2018
Related Concept Videos
Vaccinations
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Acute Pharyngitis
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
Immunodeficiency Diseases
There are three main causes of immunodeficiency...